Japan-derived evidence on drug-eluting technologies for femoropopliteal endovascular therapy: Implications for strategy, imaging, and preparation
Journal of Cardiology · 2026-11 · 88 (5) · 361-370
DOI: 10.1016/j.jjcc.2026.06.005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cardiology, 2026-11. Verfasst von Tatsuya Nakama und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Tokyo Bay Medical Center, Urayasu, Japan; Division of Vascular Surgery, Department of Surgery, The Jikei University School …. Hauptthemen laut MEDLINE: Popliteal Artery, Endovascular Procedures, Femoral Artery, Drug-Eluting Stents. Die Arbeit nennt 89 Literaturangaben.
Abstract (Originalsprache)
Over the past quarter century, endovascular therapy (EVT) for femoropopliteal artery (FPA) disease has evolved markedly with the development of dedicated devices and advances in interventional techniques. In parallel with these developments, clinical guidelines have come to clearly state EVT as a first-line treatment option. In Japan, however, the clinical landscape differs somewhat from that of other countries because of its unique healthcare and reimbursement system. Factors such as: 1) delayed approval of new devices; 2) a high prevalence of hemodialysis patients; and 3) the routine availability of intravascular ultrasound (IVUS) mean that evidence reported from other regions does not always align with daily clinical practice in Japan. Consequently, there has been a strong and ongoing demand for evidence generated in Japan and in Japanese patient populations. In response to this need, many Japanese clinicians have produced a substantial body of real-world evidence, which has had a significant impact on clinical practice worldwide, particularly in Asia. Notably, Japan has led the field in demonstrating the importance of IVUS-guided strategies, including: 1) accurate identification of guidewire passage routes; 2) precise assessment of vessel diameter and luminal area; and 3) in clarifying how these factors influence clinical outcomes. In this narrative review, we organize and summarize evidence published from Japan regarding drug-based technologies for FPA disease, with the aim of translating these findings into practical insights for daily clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Tokyo Bay Medical Center, Urayasu, Japan; Division of Vascular Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan. Electronic address: tatsuya_nakama@med.miya…
- Department of Cardiology, Tokyo Bay Medical Center, Urayasu, Japan.
Zitieren
APA
Nakama, T., Kojima, S., Kobayashi, T., Omura, Y., Kato, Y., Hanabusa, K., Asano, K., Muraishi, M., & Obunai, K. (2026). Japan-derived evidence on drug-eluting technologies for femoropopliteal endovascular therapy: Implications for strategy, imaging, and preparation. Journal of Cardiology, 88(5), 361-370. https://doi.org/10.1016/j.jjcc.2026.06.005
Vancouver
Nakama T, Kojima S, Kobayashi T, Omura Y, Kato Y, Hanabusa K, et al. Japan-derived evidence on drug-eluting technologies for femoropopliteal endovascular therapy: Implications for strategy, imaging, and preparation. Journal of Cardiology. 2026;88(5):361-370. doi:10.1016/j.jjcc.2026.06.005
BibTeX
@article{Nakama2026,
author = {Nakama, Tatsuya and Kojima, Shunsuke and Kobayashi, Tetsuya and Omura, Yuki and Kato, Yuta and Hanabusa, Katsuyuki and Asano, Kazuhiro and Muraishi, Makio and Obunai, Kotaro},
title = {Japan-derived evidence on drug-eluting technologies for femoropopliteal endovascular therapy: Implications for strategy, imaging, and preparation},
journal = {Journal of Cardiology},
year = {2026},
volume = {88},
number = {5},
pages = {361--370},
doi = {10.1016/j.jjcc.2026.06.005}
}
EUVIMED